



IQVIA Biotech in JAPAC

IQVIA Biotech in Japan and Asia-Pacific (JAPAC) provides comprehensive, flexible and fit-for-purpose clinical and commercial solutions specifically tailored to meet the regional and global aspirations of dynamic and fast-moving emerging biotech and biopharma companies.



Largest Clinical Research Organization globally and in JAPAC with unmatched scale



17,700+ sites initiated and 162K+ patients enrolled throughout JAPAC in the last five years



1,460+ studies run by therapeutically aligned teams across all areas and full spectrum integrated services

EMERGING BIOTECH CLINICAL RESEARCH IS ON THE RISE IN ASIA-PACIFIC

Clinical trial sites set up by emerging biotech and biopharma companies in Japan and Asia-Pacific have increased by over 40% each year on average, compared to just 11% across the rest of the world.¹

Asia is an increasingly critical location for clinical trials. The region accounts for close to 60% of the world's population² and presents high disease burdens, fast improving infrastructure, clinical trial recruitment and regulatory efficiencies, globally leading data management innovation, and increasingly greater government support of medical research.

IQVIA BIOTECH – A PARTNER IN ASIA-PACIFIC'S EMERGING BIOTECH AND BIOPHARMA RESEARCH RISE

IQVIA Biotech in JAPAC partners with emerging biotechs and biopharma innovators to help them achieve their global ambitions, and support with JAPAC clinical development needs, with the aim of delivering compelling results to all stakeholders and ultimately improving health outcomes for patients.

The IQVIA Biotech solutions suite in JAPAC is a custom-built delivery model that mirrors biotech organizations to offer simplified operating procedures, reduced complexity and specialized teams to provide a more agile way for emerging biotech and biopharma companies to reach their clinical and commercial milestones.

As IQVIA Biotech in JAPAC, we focus on providing tailored clinical development expertise and solutions. Additionally, we seamlessly support across other areas of the development lifecycle, specifically providing asset valuation and due diligence, drug development strategy and analytics, launch strategy and planning, as well as commercialization and lifecycle management.

For more information contact: Asiasales@iqvia.com

REFERENCES:

1. Frost & Sullivan. Asia: Preferred Destination for Clinical Trials (2020)

2. United Nations. 2018 Revision of World Urbanization Prospects. Last accessed May 2020, at <https://www.un.org/development/desa/publications/2018-revision-of-world-urbanization-prospects.html>